J Exp Pharmacol. 2020 Nov 11;12:475-485. doi: 10.2147/JEP.S259287. eCollection 2020.
Colorectal cancer is one of the top causes of cancer and cancer-related deaths worldwide. The prognosis of metastatic colorectal cancer is poor and treatment options are limited. Many patients will run out of treatment options before they become medically unfit for therapy. As such, there is a need to expand upon the current understanding of disease biology as well as drug resistance mechanisms in order to create new approaches for therapy. In this review article, we will discuss the mechanistic
rationale and clinical data for new drugs and therapeutic combinations under development for metastatic colorectal cancer.